Physiological and pathophysiological roles of NAMPT and NAD metabolism

Nature Reviews Endocrinology

Volumn 11, Issue 9, 2015, Pages 535-546

  Garten, Antje ^a   Schuster, Susanne ^a   Penke, Melanie ^a   Gorski, Theresa ^a   De Giorgis, Tommaso ^a   Kiess, Wieland ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INSULIN; LIPID; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

AGING; AMINO ACID METABOLISM; APOPTOSIS; CANCER CELL; CELL METABOLISM; ENZYME ACTIVITY; ENZYME METABOLISM; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS (TOPIC); METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; ENZYMOLOGY; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; CYTOKINES; DIABETES MELLITUS, TYPE 2; HUMANS; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY;

EID: 84939570142     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2015.117     Document Type: Review

References (197)

1. Samal, B., et al. Cloning and characterization of the cDNA encoding a novel human pre B cell colony-enhancing factor. Mol. Cell. Biol. 14, 1431-1437 (1994
2. Martin, P. R., Shea, R. J., & Mulks, M. H. Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J. Bacteriol. 183, 1168-1174 (2001
3. Rongvaux, A., et al. Pre B cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 32, 3225-3234 (2002
4. Preiss, J., & Handler, P. Enzymatic synthesis of nicotinamide mononucleotide. J. Biol. Chem. 225, 759-770 (1957
5. Fukuhara, A., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 307, 426-430 (2005
6. Chang, Y. H., Chang, D. M., Lin, K. C., Shin, S. J., & Lee, Y. J. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-Analysis and systemic review. Diabetes Metab. Res. Rev. 27, 515-527 (2011
7. Garten, A., Petzold, S., Körner, A., Imai, S., & Kiess, W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol. Metab. 20, 130-138 (2009
8. Mori, V., et al. Metabolic profiling of alternative NAD biosynthetic routes in mouse tissues. PLoS ONE. 9, e113939 (2014
9. Yang, S. J., et al. Nicotinamide improves glucose metabolism and affects the hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes. J. Nutr. Biochem. 25, 66-72 (2014
10. Collins, P. B., & Chaykin, S. The management of nicotinamide and nicotinic acid in the mouse. J. Biol. Chem. 247, 778-783 (1972
11. Ushiro, H., Yokoyama, Y., & Shizuta, Y. Purification and characterization of poly(ADP-ribose) synthetase from human placenta. J. Biol. Chem. 262, 2352-2357 (1987
12. Guan, X., Lin, P., Knoll, E., & Chakrabarti, R. Mechanism of inhibition of the human sirtuin enzyme SIRT3 by nicotinamide: computational and experimental studies. PLoS ONE. 9, e107729 (2014
13. Bitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M., & Sinclair, D. A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem. 277, 45099-45107 (2002
14. Revollo, J. R., Grimm, A. A., & Imai, S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 279, 50754-50763 (2004
15. Bieganowski, P., & Brenner, C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell. 117, 495-502 (2004
16. Nikiforov, A., Dölle, C., Niere, M., & Ziegler, M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J. Biol. Chem. 286, 21767-21778 (2011
17. Garavaglia, S., et al. The high-resolution crystal structure of periplasmic Haemophilus influenzae NAD nucleotidase reveals a novel enzymatic function of human CD73 related to NAD metabolism. Biochem. J. 441, 131-141 (2012
18. Grozio, A., et al. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-Treated tumor cells. J. Biol. Chem. 288, 25938-25949 (2013
19. Friebe, D., et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia. 54, 1200-1211 (2011
20. Kitani, T., Okuno, S., & Fujisawa, H. Growth phase-dependent changes in the subcellular localization of pre B cell colony-enhancing factor. FEBS Lett. 544, 74-78 (2003
21. Revollo, J. R., et al. Nampt/PBEF/visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6, 363-375 (2007
22. Yang, H., et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell. 130, 1095-1107 (2007
23. Pittelli, M., et al. Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J. Biol. Chem. 285, 34106-34114 (2010
24. Burgos, E. S., & Schramm, V. L. Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase. Biochemistry. 47, 11086-11096 (2008
25. Kim, M. K., et al. Crystal structure of visfatin/pre B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK 866. J. Mol. Biol. 362, 66-77 (2006
26. Wang, T., et al. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat. Struct. Mol. Biol. 13, 661-662 (2006
27. Kang, G. B., et al. Crystal structure of Rattus norvegicus visfatin/PBEF/Nampt in complex with an FK866-based inhibitor. Mol. Cells. 27, 667-671 (2009
28. Burgos, E. S., Vetticatt, M. J., & Schramm, V. L. Recycling nicotinamide. The transition-state structure of human nicotinamide phosphoribosyltransferase. J. Am. Chem. Soc. 135, 3485-3493 (2013
29. Khan, J. A., Tao, X., & Tong, L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat. Struct. Mol. Biol. 13, 582-588 (2006
30. Takahashi, R., Nakamura, S., Yoshida, T., Kobayashi, Y., & Ohkubo, T. Crystallization of human nicotinamide phosphoribosyltransferase. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 63, 375-377 (2007
31. Christensen, M. K., et al. Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-Activity relationship. J. Med. Chem. 56, 9071-9088 (2013
32. Hasmann, M., & Schemainda, I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63, 7436-7442 (2003
33. Bowlby, S. C., Thomas, M. J., D'Agostino, R. B., & Kridel, S. J. Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells. PLoS ONE. 7, e40195 (2012
34. Bruzzone, S., et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS ONE. 4, e7897 (2009
35. Koltai, E., et al. Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats. Mech. Ageing Dev. 131, 21-28 (2010
36. Van Gool, F., et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat. Med. 15, 206-210 (2009
37. Pillai, J. B., Isbatan, A., Imai, S., & Gupta, M. P. Poly(ADP-ribose) polymerase 1 dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2a deacetylase activity. J. Biol. Chem. 280, 43121-43130 (2005
38. Rodgers, J. T., Lerin, C., Gerhart-Hines, Z., & Puigserver, P. Metabolic adaptations through the PGC 1 a and SIRT1 pathways. FEBS Lett. 582, 46-53 (2008
39. Van der Horst, A., et al. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2 (SIRT1). J. Biol. Chem. 279, 28873-28879 (2004
40. Bordone, L., et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic β cells. PLoS Biol. 4, e31 (2006
41. Luo, X., & Kraus, W. L. on PAR with PARP: Cellular Stress Signaling Through Poly(ADP-ribose) and PARP 1. Genes Dev. 26, 417-432 (2012
42. Mouchiroud, L., Houtkooper, R. H., & Auwerx, J. NAD+ metabolism: a therapeutic target for age-related metabolic disease. Crit. Rev. Biochem. Mol. Biol. 48, 397-408 (2013
43. Dölle, C., Skoge, R. H., Vanlinden, M. R., & Ziegler, M. NAD biosynthesis in humans-enzymes, metabolites and therapeutic aspects. Curr. Top. Med. Chem. 13, 2907-2917 (2013
44. Chang, H. C., & Guarente, L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol. Metab. 25, 138-145 (2014
45. Imai, S., & Kiess, W. Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. Front. Biosci. (Landmark Ed.) 14, 2983-2995 (2009
46. Bürkle, A., & Virág, L. Poly(ADP-ribose): PARadigms and PARadoxes. Mol. Aspects Med. 34, 1046-1065 (2013
47. Scarpa, E. S., Fabrizio, G., & Di Girolamo, M. A role of intracellular mono ADP ribosylation in cancer biology. FEBS J. 280, 3551-3562 (2013
48. Lee, H. C., & Aarhus, R. ADP-ribosyl cyclase: an enzyme that cyclizes NAD+ into a calcium-mobilizing metabolite. Cell Regul. 2, 203-209 (1991
49. Ramsey, K. M., et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science. 324, 651-654 (2009
50. Nakahata, Y., Sahar, S., Astarita, G., Kaluzova, M., & Sassone-Corsi, P. Circadian Control of the NAD+ Salvage Pathway by CLOCK-SIRT1. Science. 324, 654-657 (2009
51. Korner, A., et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J. Clin. Endocrinol. Metab. 92, 4783-4791 (2007
52. Hallschmid, M., Randeva, H., Tan, B. K., Kern, W., & Lehnert, H. Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans. Diabetes. 58, 637-640 (2009
53. Thomas, S., et al. Seminal plasma adipokine levels are correlated with functional characteristics of spermatozoa. Fertil. Steril. 99, 1256-1263 (2013
54. Tanaka, M., et al. Visfatin is released from 3T3 L1 adipocytes via a non-classical pathway. Biochem. Biophys. Res. Commun. 359, 194-201 (2007
55. Yoon, M. J., et al. SIRT1-mediated eNAMPT secretion from adipose tissue regulates hypothalamic NAD+ and function in mice. Cell. Metab. 21, 706-717 (2015
56. Garten, A., et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem. Biophys. Res. Commun. 391, 376-381 (2010
57. Schuster, S., et al. Resveratrol differentially regulates NAMPT and SIRT1 in hepatocarcinoma cells and primary human hepatocytes. PLoS ONE. 9, e91045 (2014
58. Pillai, V. B., et al. Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling. Am. J. Physiol. Heart Circ. Physiol. 304, H415-H426 (2013
59. Zhao, B., et al. Cerebral ischemia is exacerbated by extracellular nicotinamide phosphoribosyltransferase via a non-enzymatic mechanism. PLoS ONE. 8, e85403 (2013
60. Jing, Z., et al. Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury. J. Cereb. Blood Flow Metab. 34, 1613-1621 (2014
61. Ognjanovic, S., & Bryant-Greenwood, G. D. Pre B cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am. J. Obstet. Gynecol. 187, 1051-1058 (2002
62. Kover, K., et al. Expression and regulation of nampt in human islets. PLoS ONE. 8, e58767 (2013
63. Schilling, E., & Hauschildt, S. Extracellular ATP induces P2X7-dependent nicotinamide phosphoribosyltransferase release in LPS-Activated human monocytes. Innate Immun. 18, 738-744 (2012
64. Van den Bergh, R., et al. Monocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPT. PLoS ONE. 7, e35074 (2012
65. Choi, Y. J., et al. Extracellular visfatin activates gluconeogenesis in HepG2 cells through the classical PKA/CREB-dependent pathway. Horm. Metab. Res. 46, 233-239 (2014
66. Kim, S. R., et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem. Biophys. Res. Commun. 357, 150-156 (2007
67. Bae, Y. H., et al. Upregulation of fibroblast growth factor 2 by visfatin that promotes endothelial angiogenesis. Biochem. Biophys. Res. Commun. 379, 206-211 (2009
68. Kang, Y. S., et al. Visfatin induces neurite outgrowth in PC12 cells via ERK1/2 signaling pathway. Neurosci. Lett. 504, 121-126 (2011
69. Park, H. J., et al. Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer. Oncotarget. 5, 5087-5099 (2014
70. Zamporlini, F., et al. Novel assay for simultaneous measurement of pyridine mononucleotides synthesizing activities allows dissection of NAD+ biosynthetic machinery in mammalian cells. FEBS J. 281, 5104-5119 (2014
71. Formentini, L., Moroni, F., & Chiarugi, A. Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem. Pharmacol. 77, 1612-1620 (2009
72. Hara, N., Yamada, K., Shibata, T., Osago, H., & Tsuchiya, M. Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS ONE. 6, e22781 (2011
73. Khan, M., & Joseph, F. Adipose tissue and adipokines: the association with and application of adipokines in obesity. Scientifica (Cairo) 2014, 328592 (2014
74. Olarescu, N. C., et al. Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly. J. Clin. Endocrinol. Metab. 97, 1355-1362 (2012
75. Blakemore, A. I., et al. A rare variant in the visfatin gene (NAMPT/PBEF1) is associated with protection from obesity. Obesity (Silver Spring) 17, 1549-1553 (2009
76. Saddi-Rosa, P., et al. Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects. Cardiovasc. Diabetol. 12, 119 (2013
77. Jian, W. X., et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet. Med. 23, 967-973 (2006
78. Paschou, P., et al. Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population. Cytokine. 51, 25-27 (2010
79. Körner, A., et al. Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children. Metabolism. 56, 772-777 (2007
80. Böttcher, Y., et al. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat depot specific messenger ribonucleic acid expression in humans. J. Clin. Endocrinol. Metab. 91, 2725-2731 (2006
81. Haider, D. G., et al. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia. 49, 1909-1914 (2006
82. Haider, D. G., et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J. Clin. Endocrinol. Metab. 91, 1578-1581 (2006
83. Chen, Y., Chen, M., Wu, Z., & Zhao, S. Ox-LDL induces ER stress and promotes the adipokines secretion in 3T3 L1 adipocytes. PLoS ONE. 8, e81379 (2013
84. Kralisch, S., et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3 L1 adipocytes. J. Endocrinol. 185, R1-R8 (2005
85. Kralisch, S., et al. Interleukin 6 is a negative regulator of visfatin gene expression in 3T3 L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 289, E586-E590 (2005
86. Friebe, D., et al. Impact of metabolic regulators on the expression of the obesity associated genes FTO and NAMPT in human preadipocytes and adipocytes. PLoS ONE. 6, e19526 (2011
87. Kim, H. S., et al. Blockade of visfatin induction by oleanolic acid via disturbing IL 6 TRAF6 NF ?B signaling of adipocytes. Exp. Biol. Med. (Maywood) 239, 284-292 (2014
88. Segawa, K., et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1a-dependent mechanism. Biochem. Biophys. Res. Commun. 349, 875-882 (2006
89. Curat, C. A., et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 49, 744-747 (2006
90. Romacho, T., Sánchez-Ferrer, C. F., & Peiró, C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm. 2013, 946427 (2013
91. Li, Y., et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin 6/STAT3 signaling mechanism. J. Biol. Chem. 283, 34833-34843 (2008
92. Romacho, T., et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia. 52, 2455-2463 (2009
93. Moschen, A. R., Gerner, R. R., & Tilg, H. Pre B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. Curr. Pharm. Des. 16, 1913-1920 (2010
94. Hector, J., et al. TNF a alters visfatin and adiponectin levels in human fat. Horm. Metab. Res. 39, 250-255 (2007
95. Song, H. K., et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am. J. Physiol. Renal Physiol. 295, F1485-F1494 (2008
96. Sommer, G., et al. Visfatin is a positive regulator of MCP 1 in human adipocytes in vitro and in mice in vivo. Obesity (Silver Spring) 18, 1486-1492 (2010
97. Yang, C. C., et al. Visfatin regulates genes related to lipid metabolism in porcine adipocytes. J. Anim. Sci. 88, 3233-3241 (2010
98. Salgado-Delgado, R. C., et al. Shift work or food intake during the rest phase promotes metabolic disruption and desynchrony of liver genes in male rats. PLoS ONE. 8, e60052 (2013
99. Barclay, J. L., et al. Circadian desynchrony promotes metabolic disruption in a mouse model of shiftwork. PLoS ONE. 7, e37150 (2012
100. Karlsson, B., Knutsson, A., & Lindahl, B. Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27, 485 people. Occup. Environ. Med. 58, 747-752 (2001
101. Benedict, C., et al. Diurnal rhythm of circulating nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF): impact of sleep loss and relation to glucose metabolism. J. Clin. Endocrinol. Metab. 97, E218-E222 (2012
102. Cline, M. A., Nandar, W., Prall, B. C., Bowden, C. N., & Denbow, D. M. Central visfatin causes orexigenic effects in chicks. Behav. Brain Res. 186, 293-297 (2008
103. Brunetti, L., et al. Effects of visfatin/PBEF/NAMPT on feeding behaviour and hypothalamic neuromodulators in the rat. J. Biol. Regul. Homeost. Agents. 26, 295-302 (2012
104. Cantó, C., et al. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15, 838-847 (2012
105. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02300740 (2015
106. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02191462 (2015
107. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02303483 (2015
108. Tarantino, G., & Finelli, C. What about non-Alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J. Gastroenterol. 19, 3375-3384 (2013
109. Aller, R., et al. Influence of visfatin on histopathological changes of non-Alcoholic fatty liver disease. Dig. Dis. Sci. 54, 1772-1777 (2009
110. Auguet, T., et al. Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. Clin. Biochem. 46, 202-208 (2013
111. Genc, H., et al. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann. Hepatol. 12, 548-555 (2013
112. Akbal, E., Kocak, E., Tas, A., Yuksel, E., & Koklu, S. Visfatin levels in nonalcoholic fatty liver disease. J. Clin. Lab. Anal. 26, 115-119 (2012
113. Dahl, T. B., et al. Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 95, 3039-3047 (2010
114. Gaddipati, R., et al. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Ann. Hepatol. 9, 266-270 (2010
115. Kukla, M. M., et al. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Polish J. Pathol. 61, 147-153 (2010
116. Zhang, Z. F., et al. Troxerutin improves hepatic lipid homeostasis by restoring NAD+ depletion mediated dysfunction of lipin 1 signaling in high-fat diet-Treated mice. Biochem. Pharmacol. 91, 74-86 (2014
117. Li, H., Xu, M., Lee, J., He, C., & Xie, Z. Leucine supplementation increases SIRT1 expression and prevents mitochondrial dysfunction and metabolic disorders in high-fat diet-induced obese mice. Am. J. Physiol. Endocrinol. Metab. 303, E1234-E1244 (2012
118. Tao, R., et al. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J. Biol. Chem. 286, 14681-14690 (2011
119. Castro, R. E., et al. miR 34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-Alcoholic fatty liver disease. J. Hepatol. 58, 119-125 (2013
120. Choi, S. E., et al. Elevated microRNA 34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell. 12, 1062-1072 (2013
121. Frederick, D. W., et al. Increasing NAD synthesis in muscle via nicotinamide phosphoribosyltransferase is not sufficient to promote oxidative metabolism. J. Biol. Chem. 290, 1546-1558 (2015
122. Escande, C., et al. Deleted in breast cancer 1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J. Clin. Invest. 120, 545-558 (2010
123. Choi, Y. J., et al. Involvement of visfatin in palmitate-induced upregulation of inflammatory cytokines in hepatocytes. Metabolism. 60, 1781-1789 (2011
124. Kahn, S. E., Hull, R. L., & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 444, 840-846 (2006
125. Al-Goblan, A. S., Al-Alfi, M. A., & Khan, M. Z. Mechanism linking diabetes mellitus and obesity. Diabetes. Metab. Syndr. Obes. 7, 587-591 (2014
126. Gulcelik, N. E., Usman, A., & Gürlek, A. Role of adipocytokines in predicting the development of diabetes and its late complications. Endocrine. 36, 397-403 (2009
127. Blüher, M. Adipokines-removing road blocks to obesity and diabetes therapy. Mol. Metab. 3, 230-240 (2014
128. Hug, C., & Lodish, H. F. Medicine. Visfatin: a new adipokine. Science. 307, 366-367 (2005
129. Varma, V., et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J. Clin. Endocrinol. Metab. 92, 666-672 (2007
130. Hajianfar, H., Bahonar, A., Entezari, M. H., Askari, G., & Yazdani, M. Lipid profiles and serum visfatin concentrations in patients with type II diabetes in comparison with healthy controls. Int. J. Prev. Med. 3, 326-331 (2012
131. El-Mesallamy, H. O., Kassem, D. H., El-Demerdash, E., & Amin, A. I. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism. 60, 63-70 (2011
132. Chen, M. P., et al. Elevated plasma level of visfatin/pre B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 91, 295-299 (2006
133. Lspez-Bermejo, A., et al. Serum visfatin increases with progressive β cell deterioration. Diabetes. 55, 2871-2875 (2006
134. Yilmaz, M. I., et al. Endothelial dysfunction in type 2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol. Dial. Transplant. 23, 1621-1627 (2008
135. Motawi, T. M., Shaker, O. G., El-Sawalhi, M. M., & Abdel-Nasser, Z. M. Visfatin -948G/T and resistin -420C/G. polymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseases. Genome. 57, 259-266 (2014
136. Xie, H., et al. Insulin-like effects of visfatin on human osteoblasts. Calcif. Tissue Int. 80, 201-210 (2007
137. Ramsey, K. M., Mills, K. F., Satoh, A., & Imai, S. I. Age-Associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in β cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell. 7, 78-88 (2008
138. Spinnler, R., et al. The adipocytokine Nampt and its product NMN have no effect on β cell survival but potentiate glucose stimulated insulin secretion. PLoS ONE. 8, e54106 (2013
139. Yoshino, J., Mills, K. F., Yoon, M. J., & Imai, S. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- And age-induced diabetes in mice. Cell Metab. 14, 528-536 (2011
140. Caton, P. W., Kieswich, J., Yaqoob, M. M., Holness, M. J., & Sugden, M. C. Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function. Diabetologia. 54, 3083-3092 (2011
141. Imai, S., & Guarente, L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 24, 464-471 (2014
142. Van der Veer, E., et al. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J. Biol. Chem. 282, 10841-10845 (2007
143. Villalobos, L. A., et al. Visfatin/Nampt induces telomere damage and senescence in human endothelial cells. Int. J. Cardiol. 175, 573-575 (2014
144. Song, J., et al. Nicotinamide phosphoribosyltransferase is required for the calorie restriction-mediated improvements in oxidative stress, mitochondrial biogenesis, and metabolic adaptation. J. Gerontol. A Biol. Sci. Med. Sci. 69, 44-57 (2014
145. Artegiani, B., & Calegari, F. Age-related cognitive decline: can neural stem cells help us? Aging (Albany NY) 4, 176-186 (2012
146. Stein, L. R., & Imai, S. I. Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging. EMBO J. 33, 1321-1340 (2014
147. Olszanecka-Glinianowicz, M., et al. Relationship between circulating visfatin/NAMPT, nutritional status and insulin resistance in an elderly population-results from the PolSenior substudy. Metabolism. 63, 1409-1418 (2014
148. Franceschi, C., et al. Inflamm-Aging. An evolutionary perspective on immunosenescence. Ann. NY Acad. Sci. 908, 244-254 (2000
149. Cavadini, G., et al. TNF a suppresses the expression of clock genes by interfering with E box mediated transcription. Proc. Natl Acad. Sci. USA. 104, 12843-12848 (2007
150. Warburg, O. On respiratory impairment in cancer cells. Science. 124, 269-270 (1956
151. Chiarugi, A., Dölle, C., Felici, R., & Ziegler, M. The NAD metabolome-A key determinant of cancer cell biology. Nat. Rev. Cancer. 12, 741-752 (2012
152. Schuster, S., et al. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signalling in hepatocarcinoma cells. Biochem. Biophys. Res. Commun. 458, 334-340 (2015
153. Nahimana, A., et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood. 113, 3276-3286 (2009
154. Olesen, U. H., et al. Anticancer agent CHS 828 inhibits cellular synthesis of NAD. Biochem. Biophys. Res. Commun. 367, 799-804 (2008
155. Galli, U., et al. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. J. Med. Chem. 56, 6279-6296 (2013
156. Zhou, T., Wang, T., & Garcia, J. G. Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers. Sci. Rep. 4, 6107 (2014
157. Cea, M., et al. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 120, 3519-3529 (2012
158. Thakur, B. K., et al. Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells. Int. J. Cancer. 132, 766-774 (2013
159. Zhang, K., et al. Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group. Tumour Biol. 35, 4031-4040 (2014
160. Tian, W., et al. Visfatin, a potential biomarker and prognostic factor for endometrial cancer. Gynecol. Oncol. 129, 505-512 (2013
161. Reddy, P. S., et al. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol. Ther. 7, 663-668 (2008
162. Ninomiya, S., et al. Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells. Cancer Prev. Res. (Phila.) 4, 2092-2100 (2011
163. Audrito, V., et al. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood. 125, 111-123 (2015
164. Bułdak, R. J., et al. Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study. Oncol. Rep. 29, 771-778 (2013
165. Adya, R., Tan, B. K., Punn, A., Chen, J., & Randeva, H. S. Visfatin induces human endothelial VEGF and MMP 2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc. Res. 78, 356-365 (2008
166. Olesen, U. H., et al. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. BMC Cancer. 10, 677 (2010
167. Bi, T. Q., et al. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. Oncol. Rep. 26, 1251-1257 (2011
168. Gehrke, I., et al. On-Target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells. Clin. Cancer Res. 20, 4861-4872 (2014
169. Cea, M., et al. APO866 activity in hematologic malignancies: a preclinical in vitro study. Blood. 113, 6035-6037 (2009
170. Soncini, D., et al. Nicotinamide phosphoribosyltransferase promotes epithelial to mesenchymal transition as a soluble factor independent of its enzymatic activity. J. Biol. Chem. 289, 34189-34204 (2014
171. Tan, B., et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. J. Biol. Chem. 288, 3500-3511 (2013
172. Tummala, K. S., et al. Inhibition of de novo NAD+ synthesis by oncogenic URI causes liver tumorigenesis through DNA damage. Cancer Cell. 26, 826-839 (2014
173. Von Heideman, A., Berglund, A., Larsson, R., & Nygren, P. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother. Pharmacol. 65, 1165-1172 (2010
174. Holen, K., Saltz, L. B., Hollywood, E., Burk, K., & Hanauske, A. R. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest. New Drugs. 26, 45-51 (2008
175. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00003979 (2015
176. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00724841 (2015
177. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00457574 (2015
178. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00431912 (2015
179. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00435084 (2015
180. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00432107 (2015
181. Chan, M., et al. Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption. Cancer Res. 74, 5948-5954 (2014
182. Hosseinzadeh-Attar, M. J., Golpaie, A., Janani, L., & Derakhshanian, H. Effect of weight reduction following bariatric surgery on serum visfatin and adiponectin levels in morbidly obese subjects. Obes. Facts. 6, 193-202 (2013
183. Saboori, S., et al. The comparison of serum vaspin and visfatin concentrations in obese and normal weight women. Diabetes Metab. Syndr. http://dx.doi.org/10.1016/j.dsx.2013.10.009
184. Li, R. Z., et al. Elevated visfatin levels in obese children are related to proinflammatory factors. J. Pediatr. Endocrinol. Metab. 26, 111-118 (2013
185. Jaleel, A., et al. Association of adipokines with obesity in children and adolescents. Biomark. Med. 7, 731-735 (2013
186. Terra, X., et al. Increased levels and adipose tissue expression of visfatin in morbidly obese women: the relationship with pro-inflammatory cytokines. Clin. Endocrinol. (Oxf.) 77, 691-698 (2012
187. Taskesen, D., Kirel, B., & Us, T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J. Clin. Res. Pediatr. Endocrinol. 4, 76-81 (2012
188. Catalan, V., et al. Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutr. Metab. Cardiovasc. Dis. 21, 245-253 (2011
189. Reda, R., Shehab, A., Soliman, D., Gabr, A., & Abbass, A. Serum visfatin levels in a group of Egyptian obese individuals. Egypt. J. Immunol. 18, 25-32 (2011
190. Krzystek-Korpacka, M., Patryn, E., Bednarz-Misa, I., Hotowy, K., & Noczynska, A. Visfatin in juvenile obesity-The effect of obesity intervention and sex. Eur. J. Clin. Invest. 41, 1284-1291 (2011
191. Martos-Moreno, G. Á., et al. Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism. Int. J. Obes. (Lond.) 35, 1355-1362 (2011
192. Ersoy, C., et al. Body fat distribution has no effect on serum visfatin levels in healthy female subjects. Cytokine. 49, 275-278 (2010
193. Kaminska, A., et al. An evaluation of visfatin levels in obese subjects. Endokrynol. Pol. 61, 169-173 (2010
194. Barth, S., et al. Expression of neuropeptide Y, omentin and visfatin in visceral and subcutaneous adipose tissues in humans: relation to endocrine and clinical parameters. Obes. Facts. 3, 245-251 (2010
195. Costford, S. R., et al. Skeletal muscle NAMPT is induced by exercise in humans. Am. J. Physiol. Endocrinol. Metab. 298, E117-E126 (2010
196. Nowell, M. A., et al. Regulation of pre B cell colony-enhancing factor by STAT 3 dependent interleukin 6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 54, 2084-2095 (2006
197. Bae, S. K., et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor 1. FEBS Lett. 580, 4105-4113 (2006